RAPP
Rapport Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$40.45
−3.58%Aug 5, 2026, 00:00 UTC
Rapport Therapeutics reported a net loss of $56.6 million for Q2 2026, compared to a net loss of $26.7 million in Q2 2025, with diluted EPS of -$1.19.